News & Updates
Filter by Specialty:
LDL-C test after ASCVD event improves statin adherence, intensification
Low-density lipoprotein cholesterol (LDL-C) testing appears to improve statin adherence and management in patients with a history of atherosclerotic cardiovascular disease (ASCVD), suggests a recent study.
LDL-C test after ASCVD event improves statin adherence, intensification
16 May 2022Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
Oral tebipenem pivoxil hydrobromide appears to be as good as intravenous ertapenem in the treatment of patients with complicated urinary tract infection (UTI) and acute pyelonephritis, with the two having a similar safety profile, according to data from a phase III study.
Oral tebipenem pivoxil hydrobromide works against complicated UTI, acute pyelonephritis
16 May 2022Long-term aspirin use lowers HCC risk in chronic HBV patients
Use of aspirin in the long term appears to markedly reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV), a study has shown.
Long-term aspirin use lowers HCC risk in chronic HBV patients
14 May 2022No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
No apparent link between COVID-19 vax and cerebrovascular outcomes
13 May 2022Progesterone flops for miscarriage, preterm birth prevention in PREEMPT
In pregnant women who present with first-trimester vaginal bleeding, treatment with progesterone throughout pregnancy does not appear to be beneficial in terms of lowering the risk of miscarriage or premature delivery, according to PREEMPT trial presented at this year’s American College of Obstetricians and Gynecologists (ACOG 2022) meeting.
Progesterone flops for miscarriage, preterm birth prevention in PREEMPT
13 May 2022SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.
SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
12 May 2022Early remdesivir shields transplant recipients against life-threatening COVID-19
In solid organ transplant recipients with moderate symptoms of SARS-CoV-2 infection, early administration of a 3-day remdesivir course appears to effectively prevent COVID-19-related hospitalization as well as the clinical worsening of those who are hospitalized, according to a study.